August 4, 2020 On 29 May, Lilly, working with AbCellera, launched the first human study of a monoclonal antibody—a phase I trial testing its safety and tolerability in hospitalized COVIDcampaign-pages/bispecifics/-19 patients. Full coverage on Science.
